Should I buy or sell AtriCure stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AtriCure in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ATRC shares. View ATRC analyst ratings or view top-rated stocks .

What is AtriCure's stock price target for 2024?

5 brokerages have issued 1-year target prices for AtriCure's stock. Their ATRC share price targets range from $42.00 to $68.00. On average, they predict the company's share price to reach $55.57 in the next year. This suggests a possible upside of 140.6% from the stock's current price. View analysts price targets for ATRC or view top-rated stocks among Wall Street analysts .

How have ATRC shares performed in 2024?

AtriCure's stock was trading at $35.69 at the beginning of 2024. Since then, ATRC shares have decreased by 35.3% and is now trading at $23.10. View the best growth stocks for 2024 here .

Are investors shorting AtriCure?

AtriCure saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 3,250,000 shares, an increase of 9.4% from the March 15th total of 2,970,000 shares. Based on an average trading volume of 668,700 shares, the days-to-cover ratio is presently 4.9 days. View AtriCure's Short Interest .

When is AtriCure's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024. View our ATRC earnings forecast .

How can I listen to AtriCure's earnings call?

AtriCure will be holding an earnings conference call on Wednesday, May 1st at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link .

How were AtriCure's earnings last quarter?

AtriCure, Inc. (NASDAQ:ATRC) posted its quarterly earnings results on Thursday, February, 15th. The medical device company reported ($0.21) EPS for the quarter, beating the consensus estimate of ($0.22) by $0.01. The medical device company earned $106.50 million during the quarter, compared to the consensus estimate of $103.68 million. AtriCure had a negative trailing twelve-month return on equity of 7.55% and a negative net margin of 7.62%. The firm's revenue was up 21.0% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.09) earnings per share.

What ETFs hold AtriCure's stock?

ETFs with the largest weight of AtriCure (NASDAQ:ATRC) stock in their portfolio include Harbor Corporate Culture Small Cap ETF (HAPS) and Principal Healthcare Innovators ETF (BTEC) . iShares U.S. Medical Devices ETF (IHI) .

What guidance has AtriCure issued on next quarter's earnings?

AtriCure issued an update on its FY 2024 earnings guidance on Tuesday, February, 27th. The company provided earnings per share (EPS) guidance of -0.820--0.740 for the period, compared to the consensus EPS estimate of -0.690. The company issued revenue guidance of $459.0 million-$466.0 million, compared to the consensus revenue estimate of $455.9 million.

What is Michael Carrel's approval rating as AtriCure's CEO?

38 employees have rated AtriCure Chief Executive Officer Michael Carrel on Glassdoor.com . Michael Carrel has an approval rating of 100% among the company's employees. This puts Michael Carrel in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 93.0% of employees surveyed would recommend working at AtriCure to a friend.

What other stocks do shareholders of AtriCure own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AtriCure investors own include AbbVie (ABBV) , Gilead Sciences (GILD) , Amgen (AMGN) , Vertex Pharmaceuticals (VRTX) , Enterprise Products Partners (EPD) , Abbott Laboratories (ABT) , Neurocrine Biosciences (NBIX) , NVIDIA (NVDA) , Pfizer (PFE) and Sarepta Therapeutics (SRPT) .

Who are AtriCure's major shareholders?

AtriCure's stock is owned by a variety of institutional and retail investors. Top institutional investors include Los Angeles Capital Management LLC (0.06%). Insiders that own company stock include Angela L Wirick, Angela L Wirick , David D Jr Grumhaus , Douglas J Seith , Justin J Noznesky , Karen Prange, Karl S Dahlquist, Maggie Yuen, Mark A Collar, Mark A Collar , Regina E Groves , Salvatore Privitera , Scott William Drake , Sven Wehrwein , Tonya Austin and Vinayak Doraiswamy . View institutional ownership trends .

How do I buy shares of AtriCure?

Shares of ATRC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

Does AtriCure have any subsidiaries?

The following companies are subsidiares of AtriCure: SentreHEART. Read More

NASDAQ:ATRC

AtriCure (ATRC) Stock Price, News & Analysis

→ Did You Get Your Free Bitcoin Yet? (From Crypto Swap Profits) (Ad)

Free ATRC Stock Alerts

$23.10

+0.20 (+0.87%)

(As of 04/16/2024 ET)

Compare

Today's Range: $22.42
▼
$23.35
50-Day Range: $22.90
▼
$37.78
52-Week Range: $22.42
▼
$59.61

Volume: 1.11 million shs
Average Volume: 675,861 shs
Market Capitalization: $1.12 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $55.57

Get AtriCure alerts:

AtriCure MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 140.6% Upside
$55.57 Price Target
Short Interest: Bearish
6.72% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.36
Based on 8 Articles This Week
Insider Trading: Selling Shares
$468,797 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($0.71) to ($0.47) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.63 out of 5 stars

Medical Sector

691st out of 930 stocks

Surgical & Medical Instruments Industry

74th out of 99 stocks

3.5

Analyst's Opinion

Consensus Rating
AtriCure has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
AtriCure has only been the subject of 3 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
6.72% of the outstanding shares of AtriCure have been sold short.
Short Interest Ratio / Days to Cover
AtriCure has a short interest ratio ("days to cover") of 4.9.
Change versus previous month
Short interest in AtriCure has recently increased by 9.43%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
AtriCure does not currently pay a dividend.
Dividend Growth
AtriCure does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ATRC.

1.9

News and Social Media Coverage

News Sentiment
AtriCure has a news sentiment score of 0.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.66 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 8 news articles for AtriCure this week, compared to 3 articles on an average week.
Search Interest
Only 2 people have searched for ATRC on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.
MarketBeat Follows
Only 4 people have added AtriCure to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, AtriCure insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $468,797.00 in company stock.
Percentage Held by Insiders
Only 3.20% of the stock of AtriCure is held by insiders.
Percentage Held by Institutions
99.11% of the stock of AtriCure is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for AtriCure are expected to grow in the coming year, from ($0.71) to ($0.47) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of AtriCure is -35.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of AtriCure is -35.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
AtriCure has a P/B Ratio of 2.35. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Paradigm Press

Bitcoin Rockets To Record High But Buy THIS Instead

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

>>Click here to find out what it is.

About AtriCure Stock (NASDAQ:ATRC)

AtriCure, Inc. develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure. In addition, the company sells Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.

ATRC Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ATRC Stock News Headlines

April 4, 2024 | insidertrades.com

AtriCure, Inc. (NASDAQ:ATRC) Insider Justin J. Noznesky Sells 1,500 Shares

March 21, 2024 | insidertrades.com

AtriCure, Inc. (NASDAQ:ATRC) Insider Sells $60,621.60 in Stock

April 16, 2024 | Gold Safe Exchange (Ad)

Trump’s “Tax Free” Retirement Strategy

Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.

March 17, 2024 | insidertrades.com

Karl S. Dahlquist Sells 8,231 Shares of AtriCure, Inc. (NASDAQ:ATRC) Stock

April 11, 2024 | americanbankingnews.com

AtriCure's (ATRC) Buy Rating Reiterated at Needham & Company LLC

April 10, 2024 | businesswire.com

AtriCure to Announce First Quarter 2024 Financial Results

April 9, 2024 | americanbankingnews.com

AtriCure, Inc. (NASDAQ:ATRC) Given Consensus Recommendation of "Buy" by Brokerages

March 28, 2024 | ca.finance.yahoo.com

ATRC May 2024 30.000 call

April 16, 2024 | Gold Safe Exchange (Ad)

Trump’s “Tax Free” Retirement Strategy

March 26, 2024 | finance.yahoo.com

AtriCure to Participate in the 23rd Annual Needham Virtual Healthcare Conference

March 22, 2024 | finance.yahoo.com

AtriCure (ATRC) Declined due to Concerns Over Anti-Obesity Drug

March 16, 2024 | finance.yahoo.com

ATRC Apr 2024 22.500 put

March 10, 2024 | finanznachrichten.de

Seoul Robotics Explores Partnership in Industrial Autonomous Driving R&D with UAE's Advanced Technology Research Council (ATRC)

March 7, 2024 | finance.yahoo.com

Chief Legal Officer Karl Dahlquist Sells 8,231 Shares of AtriCure Inc (ATRC)

February 28, 2024 | finance.yahoo.com

AtriCure (ATRC) Fell on Competitor Action

February 17, 2024 | finance.yahoo.com

AtriCure Full Year 2023 Earnings: EPS Beats Expectations

February 16, 2024 | realmoney.thestreet.com

AtriCure price target raised by $1 at UBS, here's why

February 16, 2024 | markets.businessinsider.com

Atricure’s Strong Growth and Market Position Justify Buy Rating and $65 Target Price

February 16, 2024 | finance.yahoo.com

AtriCure, Inc. (NASDAQ:ATRC) Q4 2023 Earnings Call Transcript

February 16, 2024 | markets.businessinsider.com

Cracking The Code: Understanding Analyst Reviews For AtriCure

February 15, 2024 | benzinga.com

Recap: AtriCure Q4 Earnings

February 15, 2024 | msn.com

Here's What Key Metrics Tell Us About AtriCure (ATRC) Q4 Earnings

February 15, 2024 | finance.yahoo.com

AtriCure Inc (ATRC) Reports Strong Revenue Growth in Q4 and Full Year 2023

February 15, 2024 | businesswire.com

AtriCure Reports Fourth Quarter 2023 and Full Year 2023 Financial Results

February 14, 2024 | msn.com

AtriCure Q4 2023 Earnings Preview

February 14, 2024 | finanznachrichten.de

Advanced Technology Research Council: Serbia Signs with UAE's ATRC to Encourage Use of Falcon AI Models at WGS 2024

February 14, 2024 | benzinga.com

AtriCure's Earnings: A Preview

See More Headlines

Receive ATRC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AtriCure and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/15/2024
Today: 4/16/2024
Next Earnings (Confirmed): 5/01/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Surgical & medical instruments
Sub-Industry: Health Care Equipment
Current Symbol: NASDAQ:ATRC
CUSIP: 04963C20
CIK: 1323885
Web: www.atricure.com
Phone: (513) 755-4100
Fax: 513-755-4567
Employees: 1,200
Year Founded: 2000

Price Target and Rating

Average Stock Price Target: $55.57
High Stock Price Target: $68.00
Low Stock Price Target: $42.00
Potential Upside/Downside: +141.5%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.66)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-30,440,000.00
Net Margins: -7.62%
Pretax Margin: -7.48%
Return on Equity: -7.55%
Return on Assets: -5.83%

Debt

Debt-to-Equity Ratio: 0.15
Current Ratio: 3.57
Quick Ratio: 2.66

Sales & Book Value

Annual Sales: $399.24 million
Price / Sales: 2.79
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $9.84 per share
Price / Book: 2.34

Miscellaneous

Outstanding Shares: 48,380,000
Free Float: 46,827,000
Market Cap: $1.11 billion
Optionable: Optionable
Beta: 1.38

Social Links

These 7 Stocks Will Be Magnificent in 2024

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives

Mr. Michael H. Carrel (Age 53)
CEO, President & Director
Comp: $1.62M
Ms. Angela L. Wirick CPA (Age 46)
Chief Financial Officer
Comp: $668.62k
Mr. Douglas J. Seith (Age 58)
Chief Operating Officer
Comp: $989.17k
Mr. Justin J. Noznesky (Age 46)
Chief Marketing & Strategy Officer
Comp: $644.73k
Ms. Deborah Yount (Age 58)
Chief Human Resources Officer
Comp: $498.36k
Mr. Salvatore Privitera J.D. (Age 57)
Chief Technical Officer
Comp: $471.15k
Dr. Vinayak Doraiswamy Ph.D. (Age 52)
Chief Scientific Officer
Comp: $777.66k
Mr. Karl S. Dahlquist CCEP (Age 54)
J.D., Chief Legal Officer
Valerie Storch-Willhaus
Vice President of Corporate Marketing & Communications

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ATRC Stock Analysis - Frequently Asked Questions

Should I buy or sell AtriCure stock right now?: 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AtriCure in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ATRC shares.
View ATRC analyst ratings or view top-rated stocks.
What is AtriCure's stock price target for 2024?: 5 brokerages have issued 1-year target prices for AtriCure's stock. Their ATRC share price targets range from $42.00 to $68.00. On average, they predict the company's share price to reach $55.57 in the next year. This suggests a possible upside of 140.6% from the stock's current price.
View analysts price targets for ATRC or view top-rated stocks among Wall Street analysts.
How have ATRC shares performed in 2024?: AtriCure's stock was trading at $35.69 at the beginning of 2024. Since then, ATRC shares have decreased by 35.3% and is now trading at $23.10.
View the best growth stocks for 2024 here.
Are investors shorting AtriCure?: AtriCure saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 3,250,000 shares, an increase of 9.4% from the March 15th total of 2,970,000 shares. Based on an average trading volume of 668,700 shares, the days-to-cover ratio is presently 4.9 days.
View AtriCure's Short Interest.
When is AtriCure's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our ATRC earnings forecast.
How can I listen to AtriCure's earnings call?: AtriCure will be holding an earnings conference call on Wednesday, May 1st at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.
How were AtriCure's earnings last quarter?: AtriCure, Inc. (NASDAQ:ATRC) posted its quarterly earnings results on Thursday, February, 15th. The medical device company reported ($0.21) EPS for the quarter, beating the consensus estimate of ($0.22) by $0.01. The medical device company earned $106.50 million during the quarter, compared to the consensus estimate of $103.68 million. AtriCure had a negative trailing twelve-month return on equity of 7.55% and a negative net margin of 7.62%. The firm's revenue was up 21.0% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.09) earnings per share.
What ETFs hold AtriCure's stock?: ETFs with the largest weight of AtriCure (NASDAQ:ATRC) stock in their portfolio include Harbor Corporate Culture Small Cap ETF (HAPS) and Principal Healthcare Innovators ETF (BTEC).iShares U.S. Medical Devices ETF (IHI).

What guidance has AtriCure issued on next quarter's earnings?: AtriCure issued an update on its FY 2024 earnings guidance on Tuesday, February, 27th. The company provided earnings per share (EPS) guidance of -0.820--0.740 for the period, compared to the consensus EPS estimate of -0.690. The company issued revenue guidance of $459.0 million-$466.0 million, compared to the consensus revenue estimate of $455.9 million.
What is Michael Carrel's approval rating as AtriCure's CEO?: 38 employees have rated AtriCure Chief Executive Officer Michael Carrel on Glassdoor.com. Michael Carrel has an approval rating of 100% among the company's employees. This puts Michael Carrel in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 93.0% of employees surveyed would recommend working at AtriCure to a friend.
What other stocks do shareholders of AtriCure own?: Based on aggregate information from My MarketBeat watchlists, some companies that other AtriCure investors own include AbbVie (ABBV), Gilead Sciences (GILD), Amgen (AMGN), Vertex Pharmaceuticals (VRTX), Enterprise Products Partners (EPD), Abbott Laboratories (ABT), Neurocrine Biosciences (NBIX), NVIDIA (NVDA), Pfizer (PFE) and Sarepta Therapeutics (SRPT).
Who are AtriCure's major shareholders?: AtriCure's stock is owned by a variety of institutional and retail investors. Top institutional investors include Los Angeles Capital Management LLC (0.06%). Insiders that own company stock include Angela L Wirick, Angela L Wirick, David D Jr Grumhaus, Douglas J Seith, Justin J Noznesky, Karen Prange, Karl S Dahlquist, Maggie Yuen, Mark A Collar, Mark A Collar, Regina E Groves, Salvatore Privitera, Scott William Drake, Sven Wehrwein, Tonya Austin and Vinayak Doraiswamy.
View institutional ownership trends.
How do I buy shares of AtriCure?: Shares of ATRC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.
Does AtriCure have any subsidiaries?: The following companies are subsidiares of AtriCure: SentreHEART.
Read More

This page (NASDAQ:ATRC) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial